C4 Therapeutics, Inc. (NASDAQ:CCCC – Get Free Report) has earned a consensus recommendation of “Hold” from the seven analysts that are currently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $9.29.
Several equities research analysts have recently commented on the stock. Stifel Nicolaus lifted their price objective on shares of C4 Therapeutics from $13.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, May 9th. Wells Fargo & Company lifted their price target on C4 Therapeutics from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 9th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $20.00 price objective on shares of C4 Therapeutics in a report on Tuesday, August 6th.
Read Our Latest Research Report on C4 Therapeutics
Institutional Inflows and Outflows
C4 Therapeutics Stock Performance
C4 Therapeutics stock opened at $6.64 on Friday. The stock has a market cap of $456.87 million, a PE ratio of -2.80 and a beta of 3.06. The stock has a 50-day moving average of $5.56 and a two-hundred day moving average of $6.66. C4 Therapeutics has a one year low of $1.06 and a one year high of $11.88.
C4 Therapeutics (NASDAQ:CCCC – Get Free Report) last announced its quarterly earnings data on Thursday, August 1st. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.11. The firm had revenue of $12.01 million during the quarter, compared to analyst estimates of $6.88 million. C4 Therapeutics had a negative net margin of 367.17% and a negative return on equity of 44.92%. As a group, sell-side analysts predict that C4 Therapeutics will post -1.56 EPS for the current fiscal year.
About C4 Therapeutics
C4 Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials.
Further Reading
- Five stocks we like better than C4 Therapeutics
- NYSE Stocks Give Investors a Variety of Quality Options
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Comparing and Trading High PE Ratio Stocks
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- Are Penny Stocks a Good Fit for Your Portfolio?
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for C4 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C4 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.